Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011

American Journal of Transplantation

Volumn 11, Issue 10, 2011, Pages 2250-2255

  Grohskopf, Lisa ^a   Uyeki, Timothy ^a   Bresee, Joseph ^a   Cox, Nancy ^a   Bridges, Carolyn ^b  

^a Influenza Div   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; TRIVALENT INACTIVATED VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ARTICLE; CLINICAL PRACTICE; EGG ALLERGY; FOOD ALLERGY; HUMAN; IMMUNIZATION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); PRIORITY JOURNAL;

CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 80053308056     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03793.x     Document Type: Article

References (35)

1. CDC. Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59 (No. RR-8).
2. CDC. Update: recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11. MMWR 2010; 59: 989-992.
3. Food and Drug Administration. February 25, 2011: Vaccines and Related Biological Products Advisory Committee meeting transcript. Rockville, Maryland: Food and Drug Administration; 2011.
4. Gross PA, Russo C, Dran S, Cataruozolo P, Munk G, Lancey SC,. Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 1997; 4: 491-492. (Pubitemid 27321787)
5. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR,. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995; 171: 198-203.
6. Foy HM, Cooney MK, McMahan R,. A/Hong Kong influenza immunity three years after immunization. JAMA 1973; 226: 758-761.
7. Ochiai H, Shibata M, Kamimura K, Niwayama S,. Evaluation of the efficacy of split-product trivalent A(H1N1), A(H3N2), and B influenza vaccines: reactogenicity, immunogenicity, and persistence of antibodies following two doses of vaccines. Microbiol Immunol 1986; 30: 1141-1149. (Pubitemid 17214723)
8. Künzel W, Glathe H, Engelmann H, Van Hoecke C,. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996; 14: 1108-1110. (Pubitemid 26348827)
9. Song JY, Cheong HJ, Hwang IS, et al,. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine 2010; 28: 3929-3935.
10. Ambrose CS, Yi T, Walker RE, Connor EM,. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008; 27: 744-748.
11. Neuzil KM, Jackson LA, Nelson J, et al,. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006; 194: 1032-1039. (Pubitemid 44547642)
12. Walter EB, Neuzil KM, Zhu Y, et al,. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics 2006; 118: e570-e578. (Pubitemid 46091608)
13. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM,. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 2006; 118: e579-e585. (Pubitemid 46091609)
14. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM,. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005; 115: 1039-1047
15. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M,. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2009; 375: 41-48.
16. Nolan T, McVernon J, Skeljo M, et al,. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303: 37-46.
17. Arguedas A, Soley C, Lindert K,. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010; 362: 370-372.
18. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60 (No. RR-2).
19. Sanofi Pasteur, Inc. Fluzone [package insert]. Swiftwater, Pennsylvania: Sanofi Pasteur, Inc.; 2011. Available at. Accessed August 15, 2011.
20. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P,. Safety of trivalent inactivated influenza vaccine in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009; 27: 2114-2120.
21. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP,. Safety of influenza vaccination in allergic children. J Infect Dis 1977; 136 (Suppl): S652-S655. (Pubitemid 8286942)
22. James JM, Zeiger RS, Lester MR, et al,. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998; 133: 624-628. (Pubitemid 28521210)
23. Esposito S, Gasparini C, Martelli A, et al,. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008; 26: 4664-4668.
24. Chung EY, Huang L, Schneider L,. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010; 125: e1024-e1030.
25. Gagnon R, Primeau MN, Des Roches A, et al,. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010; 126: 317-323.
26. Greenhawt MJ, Chernin AS, Howe L, Li JT, Sanders G,. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol 2010; 105: 387-393.
27. Owens G, MacGinnitie A,. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011; 127: 264-265.
28. Webb L, Petersen M, Boden S, et al,. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. J Allergy Clin Immunol 2011; 128: 218-219.
29. Howe LE, Conlon ASC, Greenhawt MJ, Sanders GM,. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann Allergy Asthma Immunol 2011; 106: 446-447.
30. National Institutes of Health. Guidelines for the diagnosis and management of food allergies in the United States: summary of the NIAID-sponsored expert panel report. December 2010. Available at. Accessed August 15, 2011.
31. Greenhawt MJ, Li JT,. Administering influenza vaccine to egg allergic recipients: a focused practice parameter update. Ann Allergy Asthma Immunol 201; 106: 11-16.
32. Bernstein HH,. Guidance offered on giving influenza vaccine to egg allergic patients. AAP News 2010; 31: 12.
33. Li JT, Rank MA, Squillace DL, Kita H,. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010; 125: 1412- 1413.
34. Waibel KH, Gomez R,. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. J Allergy Clin Immunol 2010; 125: 749-751.
35. Erlewyn-Lajeunesse M, Brathwaite N, Lucas JS, Warner JO,. Recommendations for the administration of influenza vaccine in children allergic to egg. BMJ 2009; 339: 912-915.